Efficacy and safety of antimicrobial de-escalation as a clinical strategy. Issue 2 (1st February 2019)

• Record Type: Journal Article
• Authors: Mathieu, Calypso; Pastene, Bruno; Cassir, Nadim; Martin-Loeches, Ignacio; Leone, Marc
• Is Part Of: Expert review of anti-infective therapy. Volume 17:Issue 2(2019)
• Page Start: 79
• Page End: 88
• Publication Date: 2019-02-01
• Subjects: Antibiotic -- antimicrobial -- de-escalation -- sepsis -- stewardship; Anti-infective agents -- Research -- Periodicals; 616.90461
• DOI: 10.1080/14787210.2019.1561275
• Languages: English
• ISSNs: 1478-7210

Abstract

ABSTRACT: Introduction : De-escalation is a widely recommended strategy in regard to guidelines, with an associated adherence to guidelines being around 50%. This review discusses data supporting de-escalation and possible obstacles for its implementation. Areas covered : Although it does not have a consensual definition, de-escalation consists of reducing the spectrum of empirical antimicrobial treatment based on the microbiological findings. Many observational studies have suggested that this strategy is likely safe and efficient for treating various types of infection. However, randomized controlled trials published as of now have not shown any improvement on the outcomes. Regarding the adverse effects of de-escalation on ecological pressure and multidrug resistance emergence, the data are contradictory. The implementation of new techniques, such as rapid diagnosis, can help guide clinicians. Expert opinion : De-escalation should be included as part of a large antibiotic stewardship program to balance the risk and benefit of each administration, and each physician prescribing antibiotics should be challenged for the quality of her/his prescription on a daily basis. In the future, one of our duties will involve determining whether a delay of antimicrobial treatment – making it possible to improve diagnostic performance and obtain the first laboratory results – is either safe or unsafe for our patients.